文献速递艾滋病与性传播感染医院感染防控

1998至2012年人类免疫缺陷病毒阳性患者造血干细胞移植的流行病学与结局:一项全国性分析

Epidemiology and Outcomes of Hematopoietic Stem Cell Transplantation in Human Immunodeficiency Virus-Positive Patients From 1998 to 2012: A Nationwide Analysis.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究利用美国全国住院患者样本数据库,分析1998至2012年接受造血干细胞移植的39517例患者,其中108例为HIV阳性。HIV阳性与阴性患者在同种异体或自体移植后的院内死亡率、插管率、脓毒症、菌血症或移植物抗宿主病方面无差异。同种异体移植中,HIV阳性患者非结核分枝杆菌和巨细胞病毒感染发生率显著更高。

要点

  • HIV阳性患者接受同种异体或自体造血干细胞移植后的院内死亡率与HIV阴性患者无差异。
  • 同种异体移植中,HIV阳性患者非结核分枝杆菌和巨细胞病毒感染发生率显著高于HIV阴性患者。
  • HIV阳性患者未出现更高的移植严重院内并发症风险,可安全进行同种异体和自体移植。

核心结论

  • HIV阳性患者某些机会性感染风险可能更高,但造血干细胞移植严重院内并发症风险未增高。
  • 同种异体和自体造血干细胞移植可在HIV阳性患者中安全进行。

研究设计与样本

  • 研究查询美国全国住院患者样本数据库1998至2012年数据,使用ICD-9-CM操作代码41.0识别造血干细胞移植。
  • HIV阳性通过ICD-9-CM诊断代码042、043、044、V08和079.53识别。
  • 共识别39517例接受造血干细胞移植的患者,其中108例为HIV感染。
  • 主要结局为院内死亡率,次要结局为造血干细胞移植院内并发症率,采用单因素、多因素回归和配对分析评估。

主要发现

  • HIV阳性与HIV阴性患者在同种异体或自体造血干细胞移植后的院内死亡率无差异。
  • HIV阳性与HIV阴性患者在插管率、脓毒症、菌血症或移植物抗宿主病方面无差异。
  • 同种异体造血干细胞移植中,HIV阳性患者非结核分枝杆菌和巨细胞病毒感染发生率显著高于HIV阴性患者。

临床怎么用

  • 作者认为,尽管HIV阳性患者某些机会性感染风险可能更高,但造血干细胞移植严重院内并发症风险未增高。
  • 作者结论指出,同种异体和自体造血干细胞移植可在HIV阳性患者中安全进行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prior studies have shown that outcomes of hematopoietic stem cell transplantation (HSCT) in human immunodeficiency virus (HIV)-positive patients have been similar to outcomes in HIV-negative patients since effective implementation of highly active antiretroviral therapy by 1998, but they are limited by small sample size or noninclusion of recent data. METHODS: We queried National Inpatient Sample, a large inpatient data set in the United States, from 1998 to 2012 for HSCT, using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code 41.0. HIV-positive patients were identified by the presence of ICD-9-CM diagnostic codes 042, 043, 044, V08, and 079.53. The primary outcome was in-hospital mortality rate, and the secondary outcome the in-hospital complication rate of HSCT. Outcomes were assessed by means of univariate, multivariate regression and matched-pair analysis. RESULTS: A total of 39517 patients who underwent HSCT were identified. Among these, 108 patients had HIV infection. There were no differences in in-hospital mortality rates or rates of intubation, sepsis, bacteremia, or graft-vs-host disease between HIV-positive and HIV-negative patients after allogeneic or autologous HSCT. In allogeneic HSCT, HIV-positive patients had a significantly higher incidence of nontuberculous mycobacterial and cytomegalovirus infection than HIV-negative patients. CONCLUSION: Although HIV-positive patients may have a higher risk of certain opportunistic infections, they are not at higher risk of serious in-hospital complications of HSCT. Allogeneic and autologous HSCT can be safely performed in HIV-positive patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mehta K, Im A, Rahman F, et al. Epidemiology and Outcomes of Hematopoietic Stem Cell Transplantation in Human Immunodeficiency Virus-Positive Patients From 1998 to 2012: A Nationwide Analysis. Clin Infect Dis. 2018. PMID: 29325063. doi:10.1093/cid/ciy010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。